对疑似进展为类风湿关节炎的关节痛患者,治疗预期或治疗本身能否改善疾病感知?
本研究纳入375例临床可疑关节痛(CSA)患者,其中236例来自TREAT EARLIER试验并随机接受甲氨蝶呤或安慰剂,139例采用观望策略。与安慰剂相比,接受甲氨蝶呤者在四个认知领域疾病感知持续改善;被提供治疗者基线时对治疗更有信心。结论认为CSA是影响疾病感知的合适时期。
要点
- 接受甲氨蝶呤者在身体不适体验、疾病对生活影响、治疗有效性和疾病持续时间四个认知领域疾病感知持续改善。
- 被提供治疗者基线时对治疗更有信心(P < 0.001),对疾病理解有更深倾向(P = 0.054)。
- 作者认为CSA是影响疾病感知的合适时期,可能为改善进展为RA患者的疾病结局提供可能。
核心结论
- 治疗预期和DMARD治疗本身均改善CSA患者的疾病感知,主要在认知领域。
- 作者认为CSA是影响疾病感知的合适时期,可能为改善进展为RA患者的疾病结局提供可能。
研究设计与样本
- 研究人群为采用观望策略未提供DMARD治疗的CSA患者,以及通过TREAT EARLIER试验被提供DMARD治疗并随后随机接受甲氨蝶呤或安慰剂的患者。
- 共研究375例CSA患者,其中236例来自TREAT EARLIER试验,139例采用观望策略。
- 疾病感知采用Brief Illness Perception Questionnaire(BIPQ)评估,涵盖认知、情绪和可理解性领域。
主要发现
- 与安慰剂相比,接受治疗者在四个认知领域疾病感知随时间持续改善:身体不适体验(P = 0.040)、疾病对生活的影响(P = 0.001)、治疗有效性(P = 0.041)和疾病持续时间(P = 0.045)。
- 基线比较显示,被提供治疗的CSA患者对治疗更有信心(P < 0.001),对疾病理解有更深倾向(P = 0.054)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Negative illness perceptions (IPs) are associated with poorer disease outcomes in rheumatoid arthritis (RA). Unfortunately, IPs are generally stable in established RA. We hypothesized that IPs, especially in the cognitive domain, are modifiable in arthralgia at risk of RA. We aimed to study if receiving DMARD treatment, or the offer of DMARD treatment associates with more positive IPs in patients with clinically suspect arthralgia (CSA). METHODS: The population studied were CSA patients to which a wait-and-see approach was adopted without offering DMARD treatment, or patients were offered DMARD treatment via the TREAT EARLIER trial and subsequently randomized to receive methotrexate or placebo. IPs were assessed using the Brief Illness Perception Questionnaire (BIPQ), covering cognitive, emotional and comprehensibility domains. The effect of DMARD treatment on IPs over time was studied by comparing the 2-year course of BIPQs of patients receiving methotrexate or placebo. The effect of offering DMARD treatment was examined by comparing the BIPQs of CSA patients in the trial with those undergoing a wait-and-see policy. RESULTS: In total, 375 CSA patients were studied, of which 236 of the TREAT EARLIER trial and 139 with a wait-and-see approach. Patients who received treatment showed sustained improvements in IPs over time compared with placebo in four cognitive domains: experience of physical complaints (P = 0.040), the illness's influence on life (P = 0.001), treatment effectiveness (P = 0.041) and disease duration (P = 0.045). Comparison at baseline showed that CSA patients to whom treatment was offered had more confidence in treatment (P < 0.001) and tended to have a deeper understanding of their disease (P = 0.054). CONCLUSION: Both the prospect of and DMARD treatment itself improved IPs in CSA, mainly in cognitive domains. These data suggest CSA as a suitable time period for influencing IPs, which may provide possibilities to improve disease outcomes in patients developing RA.
引用
- van Griethuysen SRG, Dumoulin QA, van Mulligen E, et al. Can treatment expectations or treatment itself in patients with arthralgia suspicious for progression to rheumatoid arthritis improve illness perceptions? Rheumatology (Oxford). 2025. PMID: 39945847. doi:10.1093/rheumatology/keaf095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。